Comments
“This is definitely a positive development for Ranbaxy, Sun and the entire Indian generics Industry. Ranbaxy is a great company and Sun, with its experience and understanding of the generics space, should be able to unlock the true potential and value in Ranbaxy. This unfortunately did not happen under Daiichi Sankyo which failed to harness and assimilate the complexities of running a strong generics business.”
Malvinder Singh
Former shareholder and Ranbaxy founder-family member
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.